|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase VII trial of an allogeneic cellular immunotherapy in hormone - na? ve prostate cancer 显示文摘 | Simons JW Carducci MA Mikhak B | 2006 | Clin Cancer Res2006，12，111： | 1 |
| 2 | Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II Trial 显示文摘 | Rosenbaum E Sinibaldi V Carducci MA | 2005 | Clin Cancer Res2005，11，： | 1 |
| 3 | Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial显示文摘 | ANTONARAKIS ES CARDUCCI MA EISENBERGER MA | 2012 | Cancer Chemother Pharmacol2012，69，3： | 1 |
| 4 | Phase I rapid dose-escalation study of AGS-IC4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial显示文摘 | Antonarakis ES Carducci MA Eisenberger MA | 2012 | Cancer Chemother Pharmacol2012，69，3： | 1 |
| 5 | First-in-human dose study of the Novel transforming growth factor-β receptor Ⅰ kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma显示文摘 | Rodon J Carducci MA Sepulveda-Sanchez JM | 2014 | Clin Cancer Res2014，，： | 1 |
| 6 | Endothelin receptor antagonists in the treatment of prostate cance r显示文摘 | LASSITER LK CARDUCCI MA | 2003 | Semin Oncol2003，30，5： | 1 |
| 7 | Advanced prostate cancer: the future显示文摘 | Armstrong AJ Carducci MA | 2005 | Can J Urol2005，12，2： | 1 |
| 8 | Management of bone metastases in refractory prostate cancer-role of denosunmb 显示文摘 | PALLER C J CARDUCCI MA PHILIPS GK | 2012 | Clin Interv Aging2012，7，： | 1 |
| 9 | Differentiation therapy显示文摘 | Spira AI Carducci MA | 2003 | Curr Opin Pharmacol2003，3，4： | 1 |
| 10 | A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refrac tory prostate cancer显示文摘 | CARDUCCI MA SAAD F ABRAHAMSSON PA | 2007 | Cancer2007，110，： | 1 |
| 11 | Effect of endothelin- A receptor blockade with atrasentan on tumor progression in men with hormone refractory prostate cancer: a randomized, phase H, placebo - controlled trial 显示文摘 | Carducci MA Padley R J Breul J | 2003 | J Clin Oncol2003，21，9： | 1 |
| 12 | The evolving role of docetaxel in the management of androgen in- dependent prostate cancer显示文摘 | Khan MA Carducci MA Partin AW | 2003 | J Urol2003，170，12： | 1 |
| 13 | Phenylbutyrate induces apoptosis in human prostate cancer and is more than phenylcatate 显示文摘 | Carducci MA Nelson JB Chan-Tack K | 1996 | Clin Cancer Res1996，2，2： | 1 |
| 14 | Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate 显示文摘 | Carducci MA Nelsonr JB Chan-Tack KM | 1996 | Clin Cancer Res1996，2，： | 1 |
| 15 | Prospective Evaluation of the Pharmacokinetics and Toxicity Profile of Docetaxel in the Elderly显示文摘 | Ten Tije AJ Verweij J Carducci MA | | 0，，06： | 1 |
| 16 | Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer 显示文摘 | Carducci MA Musib L Kies MS | 2006 | J Clin Oncol2006，24，： | 1 |
| 17 | Interleukin:a candidate mediator of human prostate cancer morbidity显示文摘 | Twillie DA Eisenberger MA Carducci MA | 1995 | Urology1995，45，3： | 1 |
| 18 | A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer显示文摘 | Carducci MA Saad F Abrabamsson PA | 2007 | Cancer2007，110，： | 1 |
| 19 | Advanced prostate cancer: the future 显示文摘 | Armstrong A J Carducci MA | 2005 | Can J Urol2005，12，2： | 1 |
| 20 | A phase Ⅰ trial of intravenous CG7870,a replication-selective,prostate-specific antigen-targeted oncolytic adenovirus,for the treatment of hormone-refractory,metastatic prostate cancer显示文摘 | Small EJ Carducci MA Burke JM | 2006 | Mol Ther2006，14，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员